Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 17/20 | 0.69 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
| ▸ | CTSG | P08311 | 1/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3391289 | 1.00 | CMA1 (0.69) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL999741 | 0.95 | CMA1 (0.61) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL999745 | 0.95 | CMA1 (0.61) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL8291327 | 0.94 | CMA1 (0.60) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL7908643 | 0.94 | CMA1 (0.71) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL998684 | 0.93 | CMA1 (0.70) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL999628 | 0.92 | CMA1 (0.64) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL999625 | 0.92 | CMA1 (0.64) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL3774316 | 0.91 | CMA1 (0.68) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL3774304 | 0.91 | CMA1 (0.68) | CMA1PRSS1PRSS2CTSGPRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222431-B2 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-17 | — | — | US | claimed |
| US-20090124801-A1 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-14 | — | — | US | claimed |
| EP-1716160-B1 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124801-A1 | Process for synthesizing phosphonic and phosphinic acid compounds | CMA1, PPA1, CPN1 | CMA1 1/4885PRSS1 72/4885PRSS2 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.